Market Extra: AbbVie says it will appeal $448 million antitrust judgment

AbbVie Inc. says it will appeal a $448 million judgment filed by the Federal Trade Commission, alleging that the pharmaceutical manufacturer and its partner overcharged consumers for a testosterone drug.

“We are disappointed by the ruling. We believe our conduct was lawful and the damages award is improper. We intend to appeal,” said an AbbVie spokeswoman, Toni Haubert in an emailed statement to MarketWatch.

In 2014, the FTC charged that Chicago-based AbbVie and its partner Besins Healthcare Inc. blocked consumer access to lower-cost versions of the testosterone replacement drug AndroGel.

The FTC accused AbbVie of using “sham litigation” to maintain its monopoly.

>>> Original Source <<<